
0:00
31:18
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday.
A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer.
Guests:
Alexander Drilon, MD
Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
Attending Physician, Thoracic Oncology Service
Giannis Mountzios, MD, MSc, PhD
Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit
Henry Dunant Hospital Center
Athens, Greece,
Otros episodios de "Lung Cancer Considered"



No te pierdas ningún episodio de “Lung Cancer Considered”. Síguelo en la aplicación gratuita de GetPodcast.








